Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
toxicity
Biotech
Hoth strikes back against skin toxicities but stock stays frozen
Hoth shared phase 2 results on its treatment of EGFR inhibitor-induced skin toxicities, ticking off another milestone for the candidate.
Nick Paul Taylor
Jan 22, 2026 10:38am
FDA to test tampons for lead, arsenic and other metals
Sep 11, 2024 10:00am
Merck KGaA grows Quris toxicity AI pact, continuing deal flurry
Sep 28, 2023 10:10am
Safety signal sinks Theseus' cancer program—and its share price
Jul 14, 2023 7:20am
Monopar spikes chemo side effect drug after phase 2/3 analysis
Mar 28, 2023 11:33am
Flagship fledging fetches $50M to fire drugs at specific organs
Mar 7, 2023 9:15am
